BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Optovue, Inc. Announces 19% 2009 Revenue Increase Over 2008


5/6/2010 10:11:09 AM

Optovue Announces 19% 2009 Revenue Increase Over 2008

Clinical Value and Clinical Utility prove to be the right combination in down economy

PR Newswire

FREMONT, Calif., May 6 /PRNewswire/ -- Optovue, a pioneer in fourier/spectral-domain optical coherence tomography (OCT), has announced fiscal year-end results for 2009 compared to fiscal year 2008. Despite the down economy, eye care clinicians proved that the right combination of clinical utility and clinical value is still the best package.

"Our customers around the world provided a 19% revenue increase for 2009 over 2008," stated Gordon Wong, Vice President of Finance for Optovue. "We have continuing strong support by representatives and distributor's world-wide, and all regions including the US are up significantly from 2008. The first fiscal quarter of 2010 demonstrated still another significant increase over 2009 numbers. The trend is clearly demonstrating that the clinical package offered by Optovue products is still highly desirable when faced with a number of product options."

About RTVue and iVue

RTVue was the first FDA cleared Fourier domain (also known as spectral domain) OCT launched in the United States, and also the first OCT cleared by the U.S. Food and Drug Administration for both corneal and retinal imaging. The iVue is the compact fourier-domain version of the RTVue OCT, offering the same scanning speed and resolution as the larger system, that includes scanning and reports for retina, retina nerve fiber and cornea assessment by the clinician.

About Optovue (www.optovue.com / www.ivueoct.com)

Optovue Incorporated is a privately-held ophthalmic device company dedicated to working with eye care professionals and clinical researchers to lead the commercialization of new imaging modalities that improve diagnosis and therapy of ocular disease. Optovue has achieved widespread market success through a combination of unique data analysis design, a reputation for excellent customer service, and rapid innovation of its technology in response to physician feedback. The company is headquartered in Fremont, CA, with operations in Carlsbad, CA, and European operations in Heidelberg, Germany.

Contact:

John Talarico

Vice President Regulatory

john_talarico@optovue.com

510-623-8868


Paul Kealey

Vice President Marketing

paul_kealey@optovue.com



SOURCE Optovue



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES